{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:27:29Z","timestamp":1792175249652,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic disorder that affects the cardiac myocytes leading to asymmetric hypertrophy of the left ventricle and obstruction of the left ventricular outflow tract (LVOT) with possible risk of sudden cardiac death in some high-risk patients. This paper aims to evaluate the efficacy, safety, and future prospects of aficamten in the management of HOCM and its potential to transform current standards of care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Body<\/jats:title>\n                    <jats:p>Over the years, there have been significant milestones in HOCM management, including pharmacological and surgical techniques, which have reduced the morbidity and mortality associated with this disease. However, HOCM remains a challenging disease to manage for healthcare providers due to the heterogeneous nature of its presentation and limitations to the conventional treatment medications including beta blockers and non-dihydropyridine calcium channel blockers. These traditional options often provide inadequate symptomatic relief and have significant side effects. Surgical options such as septal ablation have shown positive outcomes but are associated with procedural risks. Therefore, recent advancements have led to the development of novel agents such as cardiac myosin inhibitors (CMIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Aficamten is a new second-generation cardiac myosin inhibitor (CMI) that has shown promising results from clinical trials. With reports of reduced LVOT obstruction and improvement in heart failure symptoms, these findings indicate potential improvement in the quality of life of patients with HOCM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s43044-025-00652-0","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T02:58:50Z","timestamp":1749783530000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cardiac myosin inhibitors: Efficacy, safety and future directions of aficamten in hypertrophic obstructive cardiomyopathy"],"prefix":"10.1186","volume":"77","author":[{"given":"Ikponmwosa Jude","family":"Ogieuhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Oluwatomiwa","family":"Ajekiigbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boluwaduro Abasiekem","family":"Adeyemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bright","family":"Nwatamole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komolafe Babajide","family":"Ayodeji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oshomoh Mark-Anthony","family":"Ugiomoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temiloluwa Adebayo","family":"Odeniyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adewunmi","family":"Akingbola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efosa Peace","family":"Iyawe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olabode Olawale","family":"Oladejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motunrayo Oluwatoyosi","family":"Lawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathnael Abera","family":"Woldehana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ifeoluwa Sandra","family":"Bakare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adejumo Temilade","family":"Patience","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Chinenye","family":"Okoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"issue":"4","key":"652_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1161\/01.cir.92.4.785","volume":"92","author":"BJ Maron","year":"1995","unstructured":"Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE (1995) Prevalence of hypertrophic cardiomyopathy in a general population of young adults: Echocardiographic analysis of 4111 subjects in the CARDIA Study. Circulation 92(4):785\u2013789. https:\/\/doi.org\/10.1161\/01.cir.92.4.785","journal-title":"Circulation"},{"issue":"25","key":"652_CR2","doi-asserted-by":"publisher","first-page":"e633","DOI":"10.1161\/CIR.0000000000000945","volume":"142","author":"SR Ommen","year":"2020","unstructured":"Ommen SR, Mital S, Burke MA et al (2020) 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology\/American heart association joint committee on clinical practice guidelines (vol 142, e558, 2020). Circulation 142(25):e633. https:\/\/doi.org\/10.1161\/CIR.0000000000000945","journal-title":"Circulation"},{"issue":"2","key":"652_CR3","doi-asserted-by":"publisher","first-page":"e0211624","DOI":"10.1371\/journal.pone.0211624","volume":"14","author":"C Czimbalmos","year":"2019","unstructured":"Czimbalmos C, Csecs I, Toth A, Kiss O, Suhai FI, Sydo N, Dohy Z, Apor A, Merkely B, Vago H (2019) The demanding grey zone: Sport indices by cardiac magnetic resonance imaging differentiate hypertrophic cardiomyopathy from athlete\u2019s heart. PLoS ONE 14(2):e0211624","journal-title":"PLoS ONE"},{"issue":"4","key":"652_CR4","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/ajmg.a.61072","volume":"179","author":"D Aljeaid","year":"2019","unstructured":"Aljeaid D, Sanchez AI, Wakefield E, Chadwell SE, Moore N, Prada CE, Zhang W (2019) Prevalence of pathogenic and likely pathogenic variants in the RASopathy genes in patients who have had panel testing for cardiomyopathy. Am J Med Genet A 179(4):608\u2013614","journal-title":"Am J Med Genet A"},{"key":"652_CR5","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","volume":"121","author":"AJ Marian","year":"2017","unstructured":"Marian AJ, Braunwald E (2017) Hypertrophic cardiomyopathy genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 121:749\u2013770. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.311059","journal-title":"Circ Res"},{"issue":"6","key":"652_CR6","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.echo.2024.02.010","volume":"37","author":"M Abbasi","year":"2024","unstructured":"Abbasi M, Ong KC, Newman DB, Dearani JA, Schaff HV, Geske JB (2024) Obstruction in Hypertrophic Cardiomyopathy: Many Faces. J Am Soc Echocardiogr 37(6):613\u2013625. https:\/\/doi.org\/10.1016\/j.echo.2024.02.010","journal-title":"J Am Soc Echocardiogr"},{"key":"652_CR7","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jama.281.7.650","volume":"281","author":"BJ Maron","year":"1999","unstructured":"Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM (1999) Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 281:650\u2013655","journal-title":"JAMA"},{"issue":"5","key":"652_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1253\/circrep.CR-20-0101","volume":"3","author":"J Komatsu","year":"2021","unstructured":"Komatsu J, Imai RI, Nakaoka Y, Nishida K, Seki SI, Kubo T, Yamasaki N, Kitaoka H, Kubokawa SI, Kawai K, Hamashige N, Doi YL (2021) Importance of paroxysmal atrial fibrillation and sex differences in the prevention of embolic stroke in hypertrophic cardiomyopathy. Circ Rep. 3(5):273\u2013278. https:\/\/doi.org\/10.1253\/circrep.CR-20-0101","journal-title":"Circ Rep."},{"issue":"39","key":"652_CR9","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","volume":"35","author":"PM Elliott","year":"2014","unstructured":"Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H (2014) 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35(39):2733\u20132779. https:\/\/doi.org\/10.1093\/eurheartj\/ehu284","journal-title":"Eur Heart J"},{"key":"652_CR10","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/0735-1097(93)90386-F","volume":"21","author":"DM Gilligan","year":"1993","unstructured":"Gilligan DM, Chan WL, Joshi J, Clarke P, Fletcher A, Krikler S, Oakley CM (1993) A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. J Am Coll Cardiol 21:1672\u20131679. https:\/\/doi.org\/10.1016\/0735-1097(93)90386-F","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"652_CR11","doi-asserted-by":"publisher","first-page":"6093","DOI":"10.3390\/jcm12186093","volume":"12","author":"E Monda","year":"2023","unstructured":"Monda E, Limongelli G, Pelliccia F (2023) Hypertrophic Cardiomyopathy-Current Challenges and Future Perspectives. J Clin Med 12(18):6093. https:\/\/doi.org\/10.3390\/jcm12186093","journal-title":"J Clin Med"},{"key":"652_CR12","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1161\/01.CIR.99.22.2927","volume":"99","author":"BJ Maron","year":"1999","unstructured":"Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS (1999) Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy: A randomized, double-blind, crossover study (M-PATHY). Circulation 99:2927\u20132933. https:\/\/doi.org\/10.1161\/01.CIR.99.22.2927","journal-title":"Circulation"},{"key":"652_CR13","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1161\/01.CIR.37.4.589","volume":"37","author":"AG Morrow","year":"1968","unstructured":"Morrow AG, Fogarty TJ, Hannah H 3rd, Braunwald E (1968) Operative treatment of idiopathic hypertrophic subaortic stenosis: Techniques, and the results of preoperative and postoperative clinical and hemodynamic assessments. Circulation 37:589\u2013596","journal-title":"Circulation"},{"key":"652_CR14","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1016\/j.jacc.2018.09.064","volume":"72","author":"A Batzner","year":"2018","unstructured":"Batzner A, Pfeiffer B, Neugebauer A, Aicha D, Blank C, Seggewiss H (2018) Survival after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 72:3087\u20133094","journal-title":"J Am Coll Cardiol"},{"key":"652_CR15","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2005.02.090","volume":"46","author":"SR Ommen","year":"2005","unstructured":"Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, Gersh BJ, Ackerman MJ, McCully RB, Dearani JA, Schaff HV, Danielson GK, Tajik AJ, Nishimura RA (2005) Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 46:470\u2013476","journal-title":"J Am Coll Cardiol."},{"key":"652_CR16","doi-asserted-by":"crossref","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, Saberi S, Lakdawala NK, Wheeler MT, Owens A, Kubanek M, Wojakowski W, Jensen MK, Gimeno-Blanes J, Afshar K,Myers J, Hegde SM, Solomon SD, Sehnert AJ, Zhang D, Li W, Bhattacharya M, Edelberg JM, Waldman CB, Lester SJ, Wang A, Ho CY, Jacoby D, EXPLORER-HCM Study Investigators. (2020) Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 396:759\u2013769.","DOI":"10.1016\/S0140-6736(20)31792-X"},{"key":"652_CR17","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3390\/ijms21010226","volume":"21","author":"O Tsukamoto","year":"2020","unstructured":"Tsukamoto O (2020) Direct sarcomere modulators are promising new treatments for cardiomyopathies. Int J Mol Sci 21:226\u2013238. https:\/\/doi.org\/10.3390\/ijms21010226","journal-title":"Int J Mol Sci"},{"key":"652_CR18","doi-asserted-by":"publisher","unstructured":"Coats CJ, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, Choudhury L, Claggett B, D\u00fcngen HD, Garcia-Pavia P, Hag\u00e8ge AA, Januzzi JL, Lee MMY, Lewis GD, Ma CS, Maron MS, Miao ZM, Michels M, Olivotto I, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins H, Jacoby DL, German P, Heitner SB, Kupfer S, Lutz JD, Malik FI, Meng L, Wohltman A, Abraham TP; SEQUOIA\u2010HCM Investigators (2024) Dosing and safety profile of aficamten in symptomatic obstructive hypertrophic cardiomyopathy: Results from SEQUOIA-HCM. J Am Heart Assoc. 13(15):e035993. https:\/\/doi.org\/10.1161\/JAHA.124.035993.","DOI":"10.1161\/JAHA.124.035993"},{"issue":"8","key":"652_CR19","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/s44161-024-00505-0","volume":"3","author":"JJ Hartman","year":"2024","unstructured":"Hartman JJ, Hwee DT, Robert-Paganin J, Chuang C, Chin ER, Edell S, Lee KH, Madhvani R, Paliwal P, Pernier J, Sarkar SS, Schaletzky J, Schauer K, Taheri KD, Wang J, Wehri E, Wu Y, Houdusse A, Morgan BP, Malik FI (2024) Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy. Nat Cardiovasc Res 3(8):1003\u20131016. https:\/\/doi.org\/10.1038\/s44161-024-00505-0","journal-title":"Nat Cardiovasc Res"},{"key":"652_CR20","doi-asserted-by":"publisher","unstructured":"Zhao X, Liu H, Tian W, Fang L, Yu M, Wu X, Liu A, Wan R, Li L, Luo J, Li Y, Liu B, He Y, Chen X, Li Y, Xu D, Wang H, Han X (2013) Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of aficamten in healthy Chinese participants:a randomized, double-blind,placebo-controlled, phase 1 study. https:\/\/doi.org\/10.3389\/fphar.2023.1227470","DOI":"10.3389\/fphar.2023.1227470"},{"issue":"1","key":"652_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","volume":"81","author":"MS Maron","year":"2023","unstructured":"Maron MS, Masri A, Choudhury L, Olivotto I, Saberi S, Wang A, Garcia-Pavia P, Lakdawala NK, Nagueh SF, Rader F, Tower-Rader A, Turer AT, Coats C, Fifer MA, Owens A, Solomon SD, Watkins H, Barriales-Villa R, Kramer CM, Wong TC, Paige SL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Abraham T (2023) REDWOOD-HCM steering committee and investigators: Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 81(1):34\u201345. https:\/\/doi.org\/10.1016\/j.jacc.2022.10.020","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"652_CR22","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","volume":"390","author":"MS Maron","year":"2024","unstructured":"Maron MS, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, Choudhury L, Claggett B, Coats CJ, D\u00fcngen HD, Garcia-Pavia P (2024) Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. New England J Med 390(20):1849\u20131861. https:\/\/doi.org\/10.1056\/NEJMoa2401424","journal-title":"New England J Med"},{"key":"652_CR23","doi-asserted-by":"crossref","unstructured":"Hartman JJ, Hwee DT, Robert-Paganin J, Chuang C, Chin ER, Edell S, Lee KH, Madhvani R, Paliwal P, Pernier J, Sarkar SS (2024) Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy. Nature Cardiovascular Res 1\u20134.","DOI":"10.1038\/s44161-024-00505-0"},{"issue":"7","key":"652_CR24","first-page":"735","volume":"11","author":"JW Ostrominski","year":"2023","unstructured":"Ostrominski JW, Guo R, Elliott PM, Ho CY (2023) Cardiac myosin inhibitors for managing obstructive hypertrophic cardiomyopathy: JACC: Heart failure State-of-the-Art review. Heart Failure 11(7):735\u2013748","journal-title":"Heart Failure"},{"issue":"8","key":"652_CR25","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jacbts.2022.04.008","volume":"7","author":"FI Malik","year":"2022","unstructured":"Malik FI, Robertson LA, Armas DR, Robbie EP, Osmukhina A, Xu D, Li H, Solomon SD (2022) A phase 1 dose-escalation study of the cardiac myosin inhibitor aficamten in healthy participants. Basic Transll Sci 7(8):763\u2013775. https:\/\/doi.org\/10.1016\/j.jacbts.2022.04.008","journal-title":"Basic Transll Sci"},{"issue":"1","key":"652_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41598-022-26630-z","volume":"13","author":"AN Sharpe","year":"2023","unstructured":"Sharpe AN, Oldach MS, Rivas VN, Kaplan JL, Walker AL, Kovacs SL, Hwee DT, Cremin P, Morgan BP, Malik FI, Harris SP (2023) Effects of Aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathy. Scientif Rep 13(1):32. https:\/\/doi.org\/10.1038\/s41598-022-26630-z","journal-title":"Scientif Rep"},{"key":"652_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2024.02.020","author":"A Masri","year":"2024","unstructured":"Masri A, Sherrid MV, Abraham TP, Choudhury L, Garcia-Pavia P, Kramer CM, Barriales-Villa R, Owens AT, Rader F, Nagueh SF, Olivotto I, Saberi S, Tower-Rader A, Wong TC, Coats CJ, Watkins H, Fifer MA, Solomon SD, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Meng L, Sohn RL, Wohltman A, Maron MS, Investigators REDWOOD-HCM (2024) Efficacy and safety of aficamten in symptomatic nonobstructive hypertrophic cardiomyopathy: Results from the REDWOOD-HCM Trial, Cohort 4. J Card Fail. https:\/\/doi.org\/10.1016\/j.cardfail.2024.02.020","journal-title":"J Card Fail"},{"issue":"11","key":"652_CR28","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.cardfail.2023.07.003","volume":"29","author":"AT Owens","year":"2023","unstructured":"Owens AT, Masri A, Abraham TP, Choudhury L, Rader F, Symanski JD, Turer AT, Wong TC, TowerRader A, Coats CJ, Fifer MA, Olivotto I, Solomon SD, Watkins HC, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Meng L, Sohn R, Wohltman A, Maron MS, Investigators R-HCM (2023) Aficamten for drug-refractory severe obstructive hypertrophic cardiomyopathy in patients receiving disopyramide: REDWOOD-HCM Cohort 3. J Card Fail 29(11):1576\u20131582. https:\/\/doi.org\/10.1016\/j.cardfail.2023.07.003","journal-title":"J Card Fail"},{"issue":"1","key":"652_CR29","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1186\/s12872-024-04084-7","volume":"24","author":"M Butzner","year":"2024","unstructured":"Butzner M, Aronitz E, Cameron H, Tantakoun K, Shreay S, Drudge C (2024) An evidence review and gap analysis for obstructive hypertrophic cardiomyopathy. BMC Cardiovasc Disord 24(1):416. https:\/\/doi.org\/10.1186\/s12872-024-04084-7","journal-title":"BMC Cardiovasc Disord"},{"issue":"6","key":"652_CR30","doi-asserted-by":"publisher","first-page":"e005152","DOI":"10.1161\/JAHA.116.005152","volume":"6","author":"A Adler","year":"2017","unstructured":"Adler A, Fourey D, Weissler-Snir A, Hindieh W, Chan RH, Gollob MH, Rakowski H (2017) Safety of outpatient initiation of disopyramide for obstructive hypertrophic cardiomyopathy patients. J Am Heart Assoc 6(6):e005152. https:\/\/doi.org\/10.1161\/JAHA.116.005152","journal-title":"J Am Heart Assoc"},{"key":"652_CR31","unstructured":"A phase 3, multi-center, randomized, double-blind trial to evaluate the efficacy and safety of aficamten compared to metoprolol in adults with symptomatic obstructive hypertrophic cardiomyopathy (MAPLE-HCM) https:\/\/www.clinicaltrials.gov\/study\/NCT05767346"},{"issue":"13","key":"652_CR32","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.3390\/jcm11133898","volume":"11","author":"M Butzner","year":"2022","unstructured":"Butzner M, Rowin E, Yakubu A, Seale J, Robertson LA, Sarocco P, Maron MS (2022) Clinical characteristics and healthcare resource utilization among patients with obstructive hypertrophic cardiomyopathy treated in a range of settings in the United States. J Clin Med 11(13):3898. https:\/\/doi.org\/10.3390\/jcm11133898","journal-title":"J Clin Med"},{"issue":"1","key":"652_CR33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jchf.2023.10.004","volume":"12","author":"CJ Coats","year":"2024","unstructured":"Coats CJ, Maron MS, Abraham TP, Olivotto I, Lee MMY, Arad M, Cardim N, Ma CS, Choudhury L, D\u00fcngen HD, Garcia-Pavia P, Hag\u00e8ge AA, Lewis GD, Michels M, Oreziak A, Owens AT, Tfelt-Hansen J, Veselka J, Watkins HC, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Meng L, Wohltman A, Masri A (2024) Exercise capacity in patients with obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM baseline characteristics and study design. JACC Heart Failure 12(1):199\u2013215","journal-title":"JACC Heart Failure"},{"issue":"10","key":"652_CR34","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028693","volume":"12","author":"AM Altibi","year":"2023","unstructured":"Altibi AM, Ghanem F, Zhao Y, Elman M, Cigarroa J, Nazer B, Song HK, Masri A (2023) Hospital Procedural Volume and Clinical Outcomes Following Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy. J Am Heart Assoc 12(10):e028693. https:\/\/doi.org\/10.1161\/JAHA.122.028693","journal-title":"J Am Heart Assoc"},{"key":"652_CR35","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ahj.2021.05.007","volume":"239","author":"MY Desai","year":"2021","unstructured":"Desai MY, Okushi Y, Gaballa A, Wang Q, Geske JB, Owens AT, Saberi S, Wang A, Cremer PC, Sherrid M, Lakdawala NK, Tower-Rader A, Fermin D, Naidu SS, Lampl KL, Sehnert AJ, Nissen SE, Popovic ZB (2021) Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy. Am Heart J 239:80\u201389","journal-title":"Am Heart J"},{"issue":"6","key":"652_CR36","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/CIRCHEARTFAILURE.114.002248","volume":"8","author":"CJ Coats","year":"2015","unstructured":"Coats CJ, Rantell K, Bartnik A, Patel A, Mist B, McKenna WJ, Elliott PM (2015) Cardiopulmonary exercise testing and prognosis in hypertrophic cardiomyopathy. Circ Heart Fail 8(6):1022\u20131031. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.114.002248","journal-title":"Circ Heart Fail"},{"issue":"5","key":"652_CR37","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s40256-023-00599-0","volume":"23","author":"SA Sebastian","year":"2023","unstructured":"Sebastian SA, Padda I, Lehr EJ, Johal G (2023) Aficamten: a breakthrough therapy for symptomatic obstructive hypertrophic cardiomyopathy. Am J Cardiovascular Drugs 23(5):519\u2013532","journal-title":"Am J Cardiovascular Drugs"},{"issue":"37","key":"652_CR38","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, Bezzina CR, Biagini E, Blom NA, de Boer RA, De Winter T (2023) 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). Eur Heart J 44(37):3503\u20133626","journal-title":"Eur Heart J"},{"issue":"25","key":"652_CR39","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1016\/j.jacc.2016.08.079","volume":"68","author":"MA Burke","year":"2016","unstructured":"Burke MA, Cook SA, Seidman JG, Seidman CE (2016) Clinical and mechanistic insights into the genetics of cardiomyopathy. J Am College Cardiol 68(25):2871\u20132886","journal-title":"J Am College Cardiol"},{"issue":"7","key":"652_CR40","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMra1710575","volume":"379","author":"BJ Maron","year":"2018","unstructured":"Maron BJ (2018) Clinical course and management of hypertrophic cardiomyopathy. New England J Med 379(7):655\u2013668","journal-title":"New England J Med"},{"issue":"5","key":"652_CR41","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.jchf.2018.03.004","volume":"6","author":"BJ Maron","year":"2018","unstructured":"Maron BJ, Rowin EJ, Maron MS (2018) Global burden of hypertrophic cardiomyopathy. JACC Heart Failure. 6(5):376\u20138","journal-title":"JACC Heart Failure."},{"issue":"25","key":"652_CR42","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1016\/j.jacc.2021.10.020","volume":"78","author":"NA Ntusi","year":"2021","unstructured":"Ntusi NA, Sliwa K (2021) Associations of race and ethnicity with presentation and outcomes of hypertrophic cardiomyopathy: JACC focus seminar 6\/9. J Am College Cardiol 78(25):2573\u20132579","journal-title":"J Am College Cardiol"},{"issue":"25","key":"652_CR43","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1161\/CIRCULATIONAHA.121.053527","volume":"143","author":"H Watkins","year":"2021","unstructured":"Watkins H (2021) Time to think differently about sarcomere-negative hypertrophic cardiomyopathy. Circulation 143(25):2415\u20132417","journal-title":"Circulation"},{"issue":"17","key":"652_CR44","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.3390\/jcm12175710","volume":"12","author":"A Ottaviani","year":"2023","unstructured":"Ottaviani A, Mansour D, Molinari LV, Galanti K, Mantini C, Khanji MY, Chahal AA, Zimarino M, Renda G, Sciarra L, Pelliccia F (2023) Revisiting diagnosis and treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. J Clinical Med 12(17):5710","journal-title":"J Clinical Med"},{"issue":"8","key":"652_CR45","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40265-022-01728-w","volume":"82","author":"C Palandri","year":"2022","unstructured":"Palandri C, Santini L, Argir\u00f2 A, Margara F, Doste R, Bueno-Orovio A, Olivotto I, Coppini R (2022) Pharmacological management of hypertrophic cardiomyopathy: from bench to bedside. Drugs 82(8):889\u2013912","journal-title":"Drugs"},{"key":"652_CR46","doi-asserted-by":"crossref","unstructured":"Coats CJ, Masri A, Nassif ME, Barriales\u2010Villa R, Arad M, Cardim N, Choudhury L, Claggett B, D\u00fcngen HD, Garcia\u2010Pavia P, Hag\u00e8ge AA (2024) Dosing and safety profile of aficamten in symptomatic obstructive hypertrophic cardiomyopathy: Results from SEQUOIA\u2010HCM. J Am Heart Assoc. e035993.","DOI":"10.1161\/JAHA.124.035993"},{"issue":"13","key":"652_CR47","doi-asserted-by":"publisher","first-page":"7218","DOI":"10.3390\/ijms22137218","volume":"22","author":"C St\u0103tescu","year":"2021","unstructured":"St\u0103tescu C, Enachi \u0218, Ureche C, \u021a\u0103poi L, Anghel L, \u0218alaru D, Ple\u0219oianu C, Bostan M, Marcu D, Ovanez Balasanian M, Sasc\u0103u RA (2021) Pushing the limits of medical management in HCM: A review of current pharmacological therapy options. Int J Mol Sci 22(13):7218. https:\/\/doi.org\/10.3390\/ijms22137218","journal-title":"Int J Mol Sci"},{"key":"652_CR48","doi-asserted-by":"publisher","unstructured":"Masri A, Barriales-Villa R, Elliott P, Nassif ME, Oreziak A, Owens AT, Tower-Rader A, Heitner SB, Kupfer S, Malik FI, Melloni C, Meng L, Wei J, Saberi S, on behalf of the FOREST\u2010HCM Investigators (2024) Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: A 36-week analysis from FOREST-HCM. Eur J Heart Fail. 26(9):1993\u20131998. https:\/\/doi.org\/10.1002\/ejhf.3372.","DOI":"10.1002\/ejhf.3372"},{"issue":"11","key":"652_CR49","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1161\/CIRCULATIONAHA.122.063383","volume":"147","author":"H Rakowski","year":"2023","unstructured":"Rakowski H, Bataiosu R (2023) Can novel myosin inhibitors defer septal reduction therapy in HCM? At what risk and at what cost? Circulation 147(11):864\u2013866","journal-title":"Circulation"},{"key":"652_CR50","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.072445","author":"MY Desai","year":"2024","unstructured":"Desai MY, Wolski K, Owens A, Geske JB, Saberi S, Wang A, Sherrid M, Cremer PC, Lakdawala NK, Tower-Rader A, Fermin D, Naidu SS, Smedira NG, Schaff H, Gong Z, Mudarris L, Lampl K, Sehnert AJ, Nissen SE, VALOR-HCM investigators, (2024) Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: Week 128 results from VALOR-HCM. Circulation. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.072445","journal-title":"Circulation"}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-025-00652-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43044-025-00652-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-025-00652-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T02:58:54Z","timestamp":1749783534000},"score":1,"resource":{"primary":{"URL":"https:\/\/tehj.springeropen.com\/articles\/10.1186\/s43044-025-00652-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["652"],"URL":"https:\/\/doi.org\/10.1186\/s43044-025-00652-0","relation":{},"ISSN":["2090-911X"],"issn-type":[{"value":"2090-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}